1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine: Precision Negative Control for Src Kinase Inhibitor Studies

Executive Summary: 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (SKU B7190) is a small molecule negative control for the Src kinase inhibitor PP 2, supporting high-specificity kinase pathway research (https://www.apexbt.com/pp-3.html). This compound is supplied by APExBIO at ≥98% purity, with complete quality control documentation. It is DMSO-soluble, white to off-white, and not intended for diagnostic or therapeutic use. Its deployment in cell signaling studies allows researchers to delineate true Src kinase-dependent effects from off-target phenomena (https://angiotensin-1-2-5-7.com/index.php?g=Wap&m=Article&a=detail&id=15950). Use is recommended promptly after solution preparation, and storage at -20°C is advised for stability. These attributes make it indispensable for advanced signal transduction and cancer biology research (https://doi.org/10.1080/10715762.2024.2448483).

Biological Rationale

Protein tyrosine kinases, such as Src kinase, regulate cellular processes including proliferation, migration, and angiogenesis. Dysregulation of Src kinase is implicated in oncogenesis and metastasis. Accurate modulation and measurement of Src kinase activity are vital in cancer biology and signal transduction research. Negative control compounds like 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine are essential to distinguish true kinase inhibitor effects from off-target or nonspecific actions. The use of robust controls underpins reproducibility and specificity in target validation studies.

Mechanism of Action of 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is structurally analogous to PP 2, a potent Src kinase inhibitor. However, unlike PP 2, it does not inhibit Src kinase activity, serving as a negative control in biochemical assays (https://www.apexbt.com/pp-3.html). This allows for direct comparison of experimental responses with and without Src kinase inhibition. As a kinase inhibitor control compound, it helps attribute observed cellular effects specifically to Src kinase-dependent pathways. The compound is soluble in DMSO, facilitating precise dosing and rapid cellular uptake in in vitro systems. Its lack of Src kinase inhibition has been confirmed in comparative studies, making it a reference standard for dissecting signal transduction mechanisms.

Evidence & Benchmarks

• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine does not inhibit Src kinase activity at concentrations where PP 2 shows potent inhibition (https://www.apexbt.com/pp-3.html).
• Use as a negative control enables differentiation between Src kinase-dependent and independent effects in cell-based assays (https://angiotensin-1-2-5-7.com/index.php?g=Wap&m=Article&a=detail&id=15950).
• In vascular contractility research, inhibitors such as PP 2 (10 μM) reduce methoxamine-induced contraction, while negative controls like B7190 do not, confirming on-target specificity (https://doi.org/10.1080/10715762.2024.2448483).
• APExBIO supplies this compound with ≥98% purity and full COA/MSDS documentation, ensuring experimental reliability (https://www.apexbt.com/pp-3.html).
• Stability and solubility in DMSO are validated, supporting reproducibility in kinase inhibitor workflow integration (https://anhydrotetracycline.com/index.php?g=Wap&m=Article&a=detail&id=10897).

Applications, Limits & Misconceptions

Applications:

• Benchmarking off-target effects in protein tyrosine kinase inhibition assays.
• Control for Src kinase signaling pathway research in oncology, immunology, and vascular biology.
• Discriminating true kinase-dependent cellular responses in drug screening or mechanistic studies.
• Supporting cancer biology research where Src pathway modulation is under investigation (https://angiotensin-1-2-5-7.com/index.php?g=Wap&m=Article&a=detail&id=15956).

Limits:

• Not a therapeutic or diagnostic agent. For research use only (RUO).
• Does not inhibit any kinases, including Src, and should not be used for pathway activation/inhibition.
• Long-term storage in solution is not recommended; use solutions promptly after preparation.
• Effects in non-Src pathways are not addressed; not a general kinase pathway inhibitor control.

Common Pitfalls or Misconceptions

• Misconception: B7190 inhibits Src kinase. Correction: It is a negative control and does not inhibit Src kinase activity (https://www.apexbt.com/pp-3.html).
• Misconception: B7190 can serve as a general negative control for all kinases. Correction: It is specific for Src kinase assays paired with PP 2.
• Misconception: Long-term storage of B7190 solutions is acceptable. Correction: Solutions should be used immediately and not stored for extended periods.
• Misconception: B7190 is suitable for clinical or diagnostic use. Correction: It is intended solely for laboratory research.
• Misconception: All observed cellular effects in its presence are Src-independent. Correction: Off-target effects should still be considered and validated.

Workflow Integration & Parameters

Integrating 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine into kinase inhibitor studies involves parallel dosing with PP 2 and B7190. Use 10 μM concentration for both compounds, as validated in contractility and kinase assays (https://doi.org/10.1080/10715762.2024.2448483). Prepare fresh solutions in DMSO, store at -20°C, and minimize freeze-thaw cycles. Include B7190 in all experimental runs to control for vehicle and off-target effects. Document all control conditions as per COA guidance. This approach improves assay specificity and reproducibility in Src kinase signaling research (https://anhydrotetracycline.com/index.php?g=Wap&m=Article&a=detail&id=10897).

For expanded laboratory guidance, see this article, which discusses using B7190 for unmatched assay specificity, and this benchmark piece that details its validation versus other controls. This article updates those discussions by providing the most recent peer-reviewed evidence and integration best practices.

Conclusion & Outlook

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is the gold-standard negative control for Src kinase inhibitor PP 2 in advanced signal transduction studies. Its use enables precise attribution of cellular and molecular effects to specific kinase pathways, underpinning high-confidence conclusions in cancer biology and drug discovery. APExBIO’s rigorous supply chain and documentation further ensure reproducibility and compliance. As research progresses into more complex kinase networks, standardized controls like B7190 will remain essential for experimental rigor and data integrity (https://doi.org/10.1080/10715762.2024.2448483).